At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiplatelets; Small molecules
- Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Thrombosis
Most Recent Events
- 24 Aug 1999 Discontinued-Clinical for Cardiovascular disorders in United Kingdom (Unknown route)
- 24 Aug 1999 Discontinued-Clinical for Thrombosis in United Kingdom (Unknown route)
- 05 Oct 1998 New profile